Hansa Biopharma AB (HNSA) — Cash Flow-to-Debt Ratio
Hansa Biopharma AB (HNSA) has a Cash Flow-to-Debt Ratio of -0.09x as of June 2025, meaning its operating cash flow of Skr-111.70 Million could theoretically repay 0% of its total liabilities (Skr1.28 Billion) in one year. Explore HNSA long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hansa Biopharma AB Cash Flow-to-Debt Ratio (2008–2024)
Historical debt coverage capacity for Hansa Biopharma AB across 17 annual periods. Also explore HNSA asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Hansa Biopharma AB (2008–2024)
Year-by-year debt coverage analysis for Hansa Biopharma AB. For market capitalisation and broader financial context, see Hansa Biopharma AB stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.49x | Skr-674.88 Million | Skr1.39 Billion | ▲ +23.8% |
| 2023 | -0.64x | Skr-755.65 Million | Skr1.19 Billion | ▼ -37.5% |
| 2022 | -0.46x | Skr-502.73 Million | Skr1.08 Billion | ▲ +75.4% |
| 2021 | -1.89x | Skr-481.17 Million | Skr255.24 Million | ▼ -24.9% |
| 2020 | -1.51x | Skr-290.27 Million | Skr192.37 Million | ▲ +54.3% |
| 2019 | -3.30x | Skr-334.77 Million | Skr101.42 Million | ▼ -37.1% |
| 2018 | -2.41x | Skr-204.56 Million | Skr84.94 Million | ▲ +20.2% |
| 2017 | -3.02x | Skr-150.10 Million | Skr49.75 Million | ▲ +13.9% |
| 2016 | -3.51x | Skr-94.56 Million | Skr26.98 Million | ▲ +23.8% |
| 2015 | -4.60x | Skr-57.80 Million | Skr12.56 Million | ▲ +12.2% |
| 2014 | -5.24x | Skr-23.62 Million | Skr4.51 Million | ▼ -79.7% |
| 2013 | -2.92x | Skr-14.87 Million | Skr5.10 Million | ▲ +63.9% |
| 2012 | -8.07x | Skr-20.63 Million | Skr2.56 Million | ▼ -84.1% |
| 2011 | -4.39x | Skr-27.14 Million | Skr6.19 Million | ▼ -36.6% |
| 2010 | -3.21x | Skr-18.09 Million | Skr5.64 Million | ▼ -207.9% |
| 2009 | -1.04x | Skr-13.79 Million | Skr13.23 Million | ▲ +72.3% |
| 2008 | -3.77x | Skr-15.58 Million | Skr4.13 Million | — |